Crucell Holland, Bavarian Nordic to Develop Experimental Ebola Vaccine Regimen for HHS
Crucell Holland will move forward with work to develop experimental vaccine regimen for Ebola under a potential seven-year, $69 million contract with the preparedness and response unit of the Department of Health and Human Services. HHS said Monday the Netherlands-based pharmaceutical company will work with Denmark-based Bavarian Nordic to develop the Ad26.ZEBOV prime and MVA-BN-Filo boost components of the regimen. The […] More